| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:MRNA) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $218,807 and 2, calls, for a total amount of $70,833.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $150.0 for Moderna over the recent three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $110.0 to $150.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | TRADE | BULLISH | 08/02/24 | $6.85 | $6.5 | $6.5 | $120.00 | $65.0K | 223 | 0 |
| MRNA | CALL | SWEEP | BEARISH | 07/26/24 | $5.1 | $4.85 | $4.85 | $118.00 | $37.8K | 52 | 16 |
| MRNA | PUT | TRADE | BEARISH | 06/20/25 | $25.0 | $24.0 | $25.0 | $125.00 | $37.5K | 115 | 0 |
| MRNA | PUT | TRADE | BEARISH | 03/21/25 | $22.5 | $22.3 | $22.5 | $125.00 | $33.7K | 80 | 0 |
| MRNA | CALL | SWEEP | BULLISH | 08/16/24 | $8.3 | $8.15 | $8.25 | $120.00 | $32.9K | 3.1K | 39 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.
Posted In: MRNA
